The therapeutic utility of Interleukin-11 in the treatment of inflammatory disease

Bibliography

• ZHANG X, MORRISON DC: Lipopolysaccharide-induced selective priming effects on tumour necrosis factor al-pha and nitric oxide production in mouse peritoneal macrophages. J. Exp. Med. (1993) 177:511–516.
   PubMed Web of Science ®Google Scholar
• ALEXANDER HR, DOHERTY GM, BURESH CM, VENZON DJ, NORTON JA: A recombinent human receptor an-tagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J. Exp. Med. (1991)173:1029–1032.
   PubMed Web of Science ®Google Scholar
• DING AH, NATHAN CF, STUEHR DJ: Release of reactive nitrogen intermediates and reactive oxygen interme-diates from mouse peritoneal macrophages. Compari-son of activating cytokines and evidence for independent production. J. Immunol. (1988) 141:2407–2412.
   Google Scholar
• SONIS ST, VAN VUGT AG, MCDONALD J et al: Mitigatingeffects of interleukin 11 on consecutive courses of 5- fluorouracil-induced ulcerative mucositis in hamsters. Cytokine (1997) 9:605–612.
   PubMed Web of Science ®Google Scholar
• BREESE EJ, MICHIE CA, NICHOLLS SW et al: Tumour ne-crosis factor alpha producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology (1994) 106:1455–1466.
   PubMed Web of Science ®Google Scholar
• MACDONALD TT, HUTCHINGS P, CHOY M-Y, MURCH S,COOKE A: Tumour necrosis factor alpha and inter-feron gamma production measured at the single cell level in normal and inflamed human intestine. UM. Exp. Immunol (1990) 81:301–305.
   PubMed Web of Science ®Google Scholar
• PLEVY SE, TARGAN SR, ANDUS T, TOYOD AH: TNF-amRNA levels differentiate mucosal inflammation in Crohn's disease from ulcerative colitis. J. Immunol (1993) 150:10A.
   Web of Science ®Google Scholar
• MURCH SH, LAMKIN VA, SAVAGE MO, WALKER-SMITH JA, MACDONALD TT: Serum levels of tumour necrosis fac-tor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 32:913–917.
   PubMed Web of Science ®Google Scholar
• MAHIDA YR, WU K, JEWELL DP: Enhanced production of interleukin 1-0 by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's dis-ease. Gut (1989) 30:835–838.
   PubMed Web of Science ®Google Scholar
• LIGUMSKY M, SIMON PL, KARMELI F, RACHMILEWITZ D:Role of IL-1 in inflammatory bowel disease. Enhanced production during active disease. Gut (1990) 31:686–689.
   PubMed Web of Science ®Google Scholar
• ABREU-MARTIN MT, VIDRICH AD, LYNCH H, TARGAN SR:Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-a and ligation of Fas an-tigen. J. Immunol (1995) 155:4147–4154.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ P, HEYMAN M, CANDALH C, BLATON MA, BOUCHOUD C: Tumour necrosis factor a induces mor-phological and functional alterations of intestinal 11T29 c1.19A cell monolayers. Cytokine (1995) 7:441–448.
   Google Scholar
• MCCARTNEY-FRANCIS N, ALLEN J, MIZEL D et al.: Sup-pression of arthritis by an inhibitor of nitric oxide synthase. J. Exp. Med. (1993) 178:749–754.
   PubMed Web of Science ®Google Scholar
• GEIGER T, TOWBIN H, COSENTI-VARGAS A et al.: Neu-tralization of 11-113 activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute phase response. Clin. Exp. Rheumatol. (1993) 19:348–356.
   Google Scholar
• WILLIAMS RO, FELDMANN M, MAINI RN: . Antitumournecrosis factor ameliorates joint disease in murine collage-induced arthritis. Proc. Natl. Acad. Sci. USA (1992)89:9784–9788.
   PubMed Web of Science ®Google Scholar
• DERKX B, TAMINIAU J, RADEMA S et al.: Tumour necro-sis factor antibody treatment in Crohn's disease. Lan-cet (1993) 342:173–174.
   PubMed Web of Science ®Google Scholar
• NATHAN C, XIE Q-W: Nitric oxide synthases: roles, tolls, and controls. Cell (1994) 78:915–918.
   PubMed Web of Science ®Google Scholar
• BOGDAN C, VODOVOTZ Y, NATHAN CF: In. MononuclearPhagocytes: Activation, Role and Cytokinetics. R. van Furth, (Ed.), Kluwer Academic Publishers, Dordrecht, The Nether-lands (1991).
   Google Scholar
• EIGLER A, SINHA B, HARTMANN G, ENDRES sincerely: Taming TNF-a: strategies to restrain this proinflamma-tory cytokine. Immunol Today (1997)18:487–492.
   PubMedGoogle Scholar
• FELDMANN M, ELLIOTT MJ, WOODY JN, MAINI RN: Anti-tumour necrosis factor-alpha therapy of rheumatoid arthritis. Adv. Immunol. (1997) 64:283–350.
   PubMed Web of Science ®Google Scholar
• KOOPMAN WJ, MORELAND LW: Rheumatoid arthritis: anticytokine therapies on the horizon [Editorial]. Ann. Intern. Med. (1998)128:231–233.
   PubMed Web of Science ®Google Scholar
• PETERSON RL, BOZZA MM, DORNER AJ: Interleukin-11 induces intestinal epithelial cell growth arrest through effects on retinoblastoma protein phospho-rylation. Am. J. Pathol. (1996) 149:895–902.
   PubMed Web of Science ®Google Scholar
• TREPICCHIO WL, BOZZA M, PEDNEAULT G, DORNER AJ: Recombinant human IL-11 attenuates the inflamma-tory response through down-regulation of proinflam-matory cytokine release and nitric oxide production. J. Immunol. (1996) 157:3627–3634.
   PubMed Web of Science ®Google Scholar
• TREPICCHIO WL, WANG L, BOZZA M, DORNER AJ: IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J. Immunol (1997) 159:5661–5670.
   PubMed Web of Science ®Google Scholar
• DU XX, WILLIAMS DA: Interleukin-11: a multifunctional growth factor derived from the hematopoietic micro-environment. Blood (1994) 83:2023–2030.
   PubMed Web of Science ®Google Scholar
• DU X, LIU Q, YANG Z, ORAZI A: Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. Am. J. Physiol. (1997) 272:G545–552.
   PubMed Web of Science ®Google Scholar
• DORNER AJ, GOLDMAN SJ, KEITH JCJ: Interleukin-11: biological activity and clinical studies. BioDrugs (1997) 6:418–429.
   Web of Science ®Google Scholar
• GOLDMAN SJ: Preclinical biology of interleukin 11: amultifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem. Cells (Dayt) (1995) 13:462–471.
   PubMed Web of Science ®Google Scholar
• DU X, WILLIAMS DA: Interleukin-11: review of molecu-lar, cell biology, and clinical use. Blood (1997) 89:3897–3908.
   PubMed Web of Science ®Google Scholar
• REDLICH CA, GAO X, ROCKWELL S, KELLEY M, ELIAS JA: IL-11 enhances survival and decreases TNF-a produc-tion after radiation-induced thoracic injury. J. Immu-nol. (1996) 157:1705–1710.
   PubMed Web of Science ®Google Scholar
• LENG SX, ELIAS JA: Interleukin-11 inhibits macrophage interleukin-12 production. J. Immunol. (1997) 159:2161–2168.
   PubMed Web of Science ®Google Scholar
• BOOTH C, POTTEN CS: Effects of IL-11 on the growth ofintestinal epithelial cells in vitro. Cell Prolif (1995) 28:581–94.
   PubMed Web of Science ®Google Scholar
• ORAZI A, DU X, YANG Z, KASHAR M, WILLIA DA: Lab InvInterleukin-11 prevents apoptosis and accelerates re-covery of small intestinal mucosa in mice treated with com-bined chemotherapy and radiation. Lab. Inv. (1996) 75:33:42
   Google Scholar
• POTTEN CS: Interleukin-11 protects the clonogenicstem cells in murine small-intestinal crypts from im-pairment of their reproductive capacity by radiation. Int. J. Cancer (1995)62:356–361.
   PubMed Web of Science ®Google Scholar
• KEITH JC, ALBERT JRL, SONIS ST, PFEIFFER CJ, SCHAUB RG: IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells (1994) 1:79–89.
   Google Scholar
• QIU BS, PFEIFFER CJ, KEITH JC Jr: Protection by recombi-nant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis. Sci. (1996) 41:1625–1630.
   PubMed Web of Science ®Google Scholar
• DU XX, DOERSCHUK CM, ORAZI A, WILLIAMS DA: A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood (1994) 83:33–37.
   PubMed Web of Science ®Google Scholar
• SONIS S, MUSKA A, O'BRIEN J et al.: Alteration in the fre-quency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur. J. Cancer B. Oral Oncol. (1995) 31B:261–266.
   Google Scholar
• VAN DULLEMEN HM, VAN DEVENTER SJ, HOMMES DW et al.: Treatment of Crohn's disease with antitumour ne-crosis factor chimeric monoclonal antibody. Gastroen-terology (1995) 109:129–135.
   PubMed Web of Science ®Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's dis-ease. Crohn's Disease cA2 Study Group. New Engl. J. Med. (1997) 337:1029–35.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthri-tis. Lancet (1994) 344:1125–1127.
   PubMed Web of Science ®Google Scholar